11,148 Shares in Abbott Laboratories $ABT Bought by Worth Asset Management LLC

Worth Asset Management LLC purchased a new position in Abbott Laboratories (NYSE:ABT) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,148 shares of the healthcare product maker’s stock, valued at approximately $1,102,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. J. Stern & Co. LLP grew its holdings in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $1,603,607,000. Legal & General Group Plc bought a new position in shares of Abbott Laboratories during the second quarter worth about $1,082,524,000. Flossbach Von Storch SE acquired a new position in Abbott Laboratories in the second quarter worth about $902,938,000. Finally, Jupiter Topco LLC bought a new stake in Abbott Laboratories in the second quarter valued at about $732,788,000. 75.18% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price on the stock. Citigroup boosted their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 17th. Wells Fargo & Company raised their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, BTIG Research boosted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.88.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock traded up $0.56 on Wednesday, reaching $98.72. 3,080,576 shares of the company were exchanged, compared to its average volume of 11,312,622. The firm has a market cap of $170.81 billion, a price-to-earnings ratio of 31.94, a P/E/G ratio of 1.86 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $135.13. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company’s 50-day moving average is $106.71 and its two-hundred day moving average is $98.45.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the firm posted $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.